- Home
- VRTX
as 01-17-2025 4:00pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 104.8B | IPO Year: | 1991 |
| Target Price: | $503.92 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 30 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 02-03-2025 |
| Revenue: | $10,625,800,000 | Revenue Growth: | 10.06% |
| Revenue Growth (this year): | 12.56% | Revenue Growth (next year): | 8.34% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Nov 15 '24 | Sell | $478.56 | 15 | $7,178.40 | 25,813 | |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Nov 11 '24 | Sell | $518.27 | 3,000 | $1,554,810.00 | 44,137 | |
| Kewalramani Reshma | VRTX | CEO & President | Nov 8 '24 | Sell | $515.00 | 15,198 | $7,826,970.00 | 75,772 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
3 Unstoppable Stocks to Buy in 2025
Zacks
3 days ago
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Motley Fool
3 days ago
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Morningstar Research
4 days ago
Analyst Report: Vertex Pharmaceuticals Incorporated
Zacks
4 days ago
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock
Benzinga
5 days ago
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
Motley Fool
6 days ago
My 3 Highest-Conviction Growth Stocks to Buy in 2025
Business Wire
7 days ago
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.